Breast Cancer, Aromatase Inhibitors, and Sexual Functioning: A Pilot Study on the Effects of Vaginal Testosterone Therapy
No Thumbnail Available
Authors
Dahir, Melissa
Travers-Gustafson, Dianne
Issue Date
2014-05-21 , 2014-05-21
Type
Manuscript
Language
Keywords
Alternative Title
Vaginal Testosterone and Breast Cancer
Abstract
Introduction. Women with breast
cancer have better cancer-related outcomes with
the use of aromatase inhibitors (AIs), but the
physiological suppression of estradiol can
negatively affect sexual functioning due to
unpleasant urogenital and vaginal symptoms.
Local health care practitioners have observed
that the benefits of vaginal testosterone in
allaying these unpleasant symptoms in women
with breast cancer are similar to the benefits of
vaginal estrogen in women without breast
cancer.
Aim. To evaluate the effects of using a daily vaginal testosterone cream on the reported
sexual health quality of life in women with
breast cancer taking AI therapy.
Methods. Thirteen postmenopausal
women with breast cancer on AI therapy and
experiencing symptoms of sexual dysfunction
were recruited from an oncology practice. The
women were prescribed a 300 microgram (μg)
testosterone vaginal cream daily for 4 weeks.
During the first study visit, a vaginal swab was
obtained to rule out the presence of Candida
species or Gardnerella vaginalis in participants.
Women with positive vaginal swabs were
treated prior to starting the vaginal testosterone
therapy.
Main outcome measure. The Female
Sexual Function Index (FSFI) survey,
measuring female sexual health quality of life,
was administered during the first study visit and
at the final study visit, after completing
testosterone therapy.
Results. Twelve patients completed four
weeks of daily vaginal testosterone therapy.
When compared to baseline FSFI scores, there
was a statistically significant improvement for
Name:
Melissa
Dahir
NetID:
mad30977
individual domain scores of desire (P=0.000),
arousal (P=0.002), lubrication (P=0.018),
orgasm (P=.005), satisfaction (P=0.001), and
pain (P=0.000). Total domain scores reflecting
sexual health quality of life also improved when
compared to baseline (P=0.000).
Conclusions. The use of a compounded
testosterone vaginal cream applied daily for four
weeks improves reported sexual health quality
of life in women with breast cancer taking AIs.
Introduction: Women with breast cancer have better cancer-related outcomes with the use of aromatase inhibitors (AIs), but the physiological suppression of estradiol can negatively affect sexual functioning due to unpleasant urogenital and vaginal symptoms. Local health care practitioners have observed that the benefits of vaginal testosterone in allaying these unpleasant symptoms in women with breast cancer are similar to the benefits of vaginal estrogen in women without breast cancer.|Aim: To evaluate the effects of using a daily vaginal testosterone cream on the reported sexual health quality of life in women with breast cancer taking AI therapy.|Methods: Thirteen postmenopausal women with breast cancer on AI therapy and experiencing symptoms of sexual dysfunction were recruited from an oncology practice. The women were prescribed a 300 microgram (μg) testosterone vaginal cream daily for 4 weeks. During the first study visit, a vaginal swab was obtained to rule out the presence of Candida species or Gardnerella vaginalis in participants. Women with positive vaginal swabs were treated prior to starting the vaginal testosterone therapy.|Main outcome measure: The Female Sexual Function Index (FSFI) survey, measuring female sexual health quality of life, was administered during the first study visit and at the final study visit, after completing testosterone therapy.|Results. Twelve patients completed four weeks of daily vaginal testosterone therapy. When compared to baseline FSFI scores, there was a statistically significant improvement for individual domain scores of desire (P=0.000), arousal (P=0.002), lubrication (P=0.018), orgasm (P=.005), satisfaction (P=0.001), and pain (P=0.000). Total domain scores reflecting sexual health quality of life also improved when compared to baseline (P=0.000).|Conclusions. The use of a compounded testosterone vaginal cream applied daily for four weeks improves reported sexual health quality of life in women with breast cancer taking AIs.
Introduction: Women with breast cancer have better cancer-related outcomes with the use of aromatase inhibitors (AIs), but the physiological suppression of estradiol can negatively affect sexual functioning due to unpleasant urogenital and vaginal symptoms. Local health care practitioners have observed that the benefits of vaginal testosterone in allaying these unpleasant symptoms in women with breast cancer are similar to the benefits of vaginal estrogen in women without breast cancer.|Aim: To evaluate the effects of using a daily vaginal testosterone cream on the reported sexual health quality of life in women with breast cancer taking AI therapy.|Methods: Thirteen postmenopausal women with breast cancer on AI therapy and experiencing symptoms of sexual dysfunction were recruited from an oncology practice. The women were prescribed a 300 microgram (μg) testosterone vaginal cream daily for 4 weeks. During the first study visit, a vaginal swab was obtained to rule out the presence of Candida species or Gardnerella vaginalis in participants. Women with positive vaginal swabs were treated prior to starting the vaginal testosterone therapy.|Main outcome measure: The Female Sexual Function Index (FSFI) survey, measuring female sexual health quality of life, was administered during the first study visit and at the final study visit, after completing testosterone therapy.|Results. Twelve patients completed four weeks of daily vaginal testosterone therapy. When compared to baseline FSFI scores, there was a statistically significant improvement for individual domain scores of desire (P=0.000), arousal (P=0.002), lubrication (P=0.018), orgasm (P=.005), satisfaction (P=0.001), and pain (P=0.000). Total domain scores reflecting sexual health quality of life also improved when compared to baseline (P=0.000).|Conclusions. The use of a compounded testosterone vaginal cream applied daily for four weeks improves reported sexual health quality of life in women with breast cancer taking AIs.
Description
Citation
Publisher
License
Copyright is retained by the Author. A non-exclusive distribution right is granted to Creighton University
Melissa Dahir, DNP, FNP-‐C owns the copyright to the manuscript titled: Breast Cancer, Aromatase Inhibitors, and Sexual Functioning: A Pilot Study on the Effects of Vaginal Testosterone Therapy.
Melissa Dahir, DNP, FNP-‐C owns the copyright to the manuscript titled: Breast Cancer, Aromatase Inhibitors, and Sexual Functioning: A Pilot Study on the Effects of Vaginal Testosterone Therapy.